We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
News

Gyros and GE Healthcare Life Sciences Sign Distribution Agreement

Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
News

Gyros and GE Healthcare Life Sciences Sign Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros and GE Healthcare Life Sciences Sign Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

 

The Gyros platform is increasingly used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.

Commenting on the announcement, Erik Walldén, CEO at Gyros, said, “The growing acceptance of our nanoliter-scale immunoassay platform within the global biopharmaceutical industry makes it imperative that we are represented within the Japanese market. We believe that this agreement with GE Healthcare Life Sciences will be a key factor in our success. As well as the clear commercial synergy between our product portfolios, we can be sure of providing the highest standards of service and support for our Japanese customers. We look forward to a highly successful collaboration.”

Hiroko Watanabe, General Manager GE Healthcare Life Sciences, Japan, added, “We are delighted to have signed this agreement with Gyros which will help us expand our offering of value-added and innovative technologies to the biopharmaceutical industry in Japan. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry including Biacore(™) and MicroCal(™) systems.

Advertisement